- Company to reduce workforce by approximately one-quarter, reduce expenses
and focus primarily on novel cancer program -
REDWOOD CITY, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced a corporate realignment to reduce expenses and focus its activities on its hypoxia-activated prodrug (HAP) program and the currently ongoing clinical trials of glufosfamide.
Corporate Realignment
The Company is committed to reducing cash burn and refocusing its research and development efforts. The Company is taking the following actions:
-- The Company will realign several areas of its operations and reduce
staff by approximately one-quarter from 44 employees to 32. As part of
this action, Cathleen Davis, the Company's vice president, Finance and
Controller and Kevin Kaster, the Company's senior vice president,
Corporate Development will leave the Company. Joel Fernandes, who is
currently the Company's assistant controller, will serve as senior
director, Finance and Controller, effective November 2, 2007. Cathleen
Davis and Kevin Kaster will continue to serve the Company as
consultants.
-- The Company is planning to reduce consulting and other external
expenses.
In connection with these actions, Threshold expects to pay severance
benefits of approximately $1.2 million in the fourth quarter of 2007. The
Company continues to expect cash used for operations to be in the range of
$30 to $35 million in 2007. The Company currently expects cash and
investments to be sufficient to fund projected activities at least through
the first quarter of 2009. As of Ju
'/>"/>
| SOURCE Threshold Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |